Related Experiment Video
Updated: Aug 9, 2026

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
Published on: February 27, 2014
NSAID-induced acute phase response is due to increased intestinal permeability and characterized by early and
Stuart Tugendreich1, Cecelia I Pearson, John Sagartz
1Iconix Pharmaceuticals Inc., Mountain View, California 94043, USA.
Abstract:
Toxicogenomics using a reference database can provide a better understanding and prediction of toxicity, largely by creating biomarkers that tie gene expression to actual pathology events. During the course of building a toxicogenomic database, an observation was made that a number of non-steroidal anti-inflammatory compounds (NSAIDs) at supra-pharmacologic doses induced an acute phase response (APR) and displayed hepatic gene expression patterns similar to that of intravenous lipopolysaccharide (LPS). Since NSAIDs are known to cause injury along the gastrointestinal tract, it has been suggested that NSAIDs increase intestinal permeability, allowing LPS and/or bacteria into the systemic circulation and stimulating an APR detectable in the liver. A short term study was subsequently conducted examining the effects of aspirin, indomethacin, ibuprofen, and rofecoxib to rats and a variety of endpoints were examined that included serum levels of inflammatory cytokines, histologic evaluation, and hepatic gene expression. Both indomethacin and ibuprofen injured the gastrointestinal tract, induced an APR, and increased serum levels of LPS, while rofecoxib and aspirin did not affect the GI tract or induce an APR. In treatments that eventually showed a systemic inflammatory response, hepatic expression of many inflammatory genes was noted as early as 6 hours after treatment well before alterations in traditional clinical pathology markers were detected. This finding led to the creation of a hepatic gene expression biomarker of APR that was effectively shown to be an early identifier of imminent inflammatory injury. In terms of the relative gastrointestinal safety and the NSAIDs studied, an important safety distinction can be made between the presumptive efficacious dose and the APR-inducing dose for indomethacin (1-2-fold), ibuprofen (5-fold), and rofecoxib (approximately 250-fold). Our data support the notion that NSAID-induced intestinal injury results in leakage of commensural bacteria and/or LPS into the circulation, provoking a systemic inflammatory response and that hepatic gene expression-based biomarkers can be used as early and sensitive biomarkers of APR onset.
Insights
Non-steroidal anti-inflammatory drugs (NSAIDs) can trigger a systemic inflammatory response by increasing gut permeability and allowing lipopolysaccharide (LPS) into circulation. Hepatic gene expression serves as an early biomarker for this acute phase response (APR).
Area of Science:
- Toxicogenomics
- Pharmacology
- Biomarker Discovery
Background:
- Non-steroidal anti-inflammatory drugs (NSAIDs) are known to cause gastrointestinal injury.
- NSAID-induced intestinal injury may lead to increased intestinal permeability, allowing lipopolysaccharide (LPS) translocation.
- This translocation can trigger a systemic acute phase response (APR) detectable in the liver.
Purpose of the Study:
- To investigate the relationship between NSAID-induced gastrointestinal injury and the acute phase response (APR).
- To evaluate hepatic gene expression as an early biomarker for NSAID-induced APR.
- To assess the gastrointestinal safety profiles of various NSAIDs.
Main Methods:
- A short-term study in rats treated with aspirin, indomethacin, ibuprofen, and rofecoxib.
- Examination of serum inflammatory cytokines, histologic evaluation, and hepatic gene expression.
- Analysis of serum LPS levels and gastrointestinal pathology.
Main Results:
- Indomethacin and ibuprofen caused gastrointestinal injury, induced APR, and increased serum LPS levels.
- Aspirin and rofecoxib did not significantly affect the gastrointestinal tract or induce APR.
- Hepatic gene expression of inflammatory genes was altered as early as 6 hours post-treatment, preceding traditional clinical pathology markers.
- A hepatic gene expression biomarker for APR was developed, demonstrating early identification of inflammatory injury.
Conclusions:
- NSAID-induced intestinal injury leads to LPS translocation, provoking a systemic inflammatory response.
- Hepatic gene expression serves as an early and sensitive biomarker for the onset of APR.
- Significant differences in gastrointestinal safety were observed among the studied NSAIDs, with rofecoxib showing a wider margin between efficacious and APR-inducing doses.
Related Concept Videos
Inflammatory Bowel Disease II: Ulcerative Colitis
Acute Inflammation I: Inflammatory Response
Inflammatory Bowel Disease III: Crohn's Disease
Acute Inflammation III: Local and Systemic Effects
Peptic Ulcer Disease II: Pathophysiology
Acute Inflammation II: Cellular Phase
